Macromolecular Modeling Blog ™

This is the third post in the CAPRI series, summarizing the presentations of Jeffrey Gray, Zhiping Weng, and Miriam Eisenstein, as provided by the speakers. More to appear in the continuation of the series.
(more…)

In a post yesterday on the Bleeding Edge Biotech Blog, Adam Kraut gives an expanded version of his article for Bio-IT World entitled Antibody Docking on the Amazon Cloud describing how Pfizer is leveraging the power and flexibility of cloud computing to run antibody docking simulations using Rosetta. Pfizer employed BioTeam (which Kraut consults for) to port Rosetta to the cloud. This is a fascinating article and certainly the Pfizer/BioTeam/Rosetta/Amazon synergy is a phenomenon on the bleeding edge.

I would add to the article that Jeffrey Gray at Johns Hopkins University was the lead developer of RosettaDock and RosettaAntibody. Rosetta has become synonymous with David Baker (and for good reason), but it is important to acknowledge continuing contributions to Rosetta outside of the Baker lab. Scientific collaborations can dissolve quickly when recognition is unevenly distributed, whether internally or as a result of outside perceptions (i.e. not as the result of any intentions by researchers in the collaboration).

If you use or write about Rosetta, please help us keep this unique collaboration going by acknowledging and citing the individual developers and researchers and their current labs!!!!

Please see the RosettaDock Webinar post for more details.

We have recently conducted a poll amongst people interested in learning more about the Rosetta software (as a preliminary step to the Rosetta Academic Training Workshop). One of the questions in that poll was: “Which Rosetta related topics is of the most interest to you?” The results (from ~200 participants) are summarized in the graph below.

Interest trends amongst Rosetta users

Protein-protein docking was chosen as the topic with the highest interest level, with a slight gap from ab-initio structure prediction and protein-ligand docking. This correlates well with another superficial analysis we made a while back (What’s trendy in structural bioinformatics) in which we showed qualitatively that docking receives the most interest from ‘Cite U Like‘ structural bioinformaticians. It is worth noting that Molecular Dynamics was not included, since Rosetta is not intended for MD simulations.

What is your field in structural bioinformatics? Anyone has more evidence for the increase in interest in protein-protein docking?